Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats

Hypertension

Volumn 29, Issue 5, 1997, Pages 1204-1210

  Lake, Kristy D ^a   Martin, Billy R ^a   Kunos, George ^a   Varga, Károly ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

blood pressure; cannabinoids; heart rate; hypotension

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; TETRAHYDROCANNABINOL; TUBOCURARINE CHLORIDE; URETHAN;

ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR EFFECT; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; GENERAL ANESTHESIA; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0030991629     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1204     Document Type: Article

References (41)

1. 9-THC (cannabis) on cardiac performance with or without beta blockade. Circulation. 1976;53:703-709.
2. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydro-cannabinol ingestion. Clin Pharmacol Ther. 1975;18: 287-297.
3. Dewey WL, Harris LS, Howes JF, Kennedy JS, Granchelli FE, Pars HG, Razdan RK. Pharmacology of some marijuana constituents and two heterocyclic analogues. Nature. 1970;226:1265-1276.
4. 9(11)-tetrahydrocannabinol and their interaction with epinephrine. Life Sci. 1987;41:79-87.
5. Graham JDP, Li DMF. Cardiovascular and respiratory effects of cannabis in cat and rat. Br J Pharmacol. 1973;49:1-10.
6. Stark P, Dews PB. Cannabinoids II: cardiovascular effects. J Pharmacol Exp Ther. 1980;214:131-138.
7. 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 1974;26:186-192.
8. 9-tetrahydrocannabinol of the blood pressure of hypertensive rats bearing regenerated adrenal glands. Br J Pharmacol. 1973;48:169-171.
9. Nahas GG, Schwartz IW, Adamec J, Manger WM. Tolerance to delta-9-tetrahydrocannabinol in the spontaneously hypertensive rat. Proc Soc Exp Biol Med. 1973;142:58-60.
10. 9-trans-tetra-hydrocannabinol: a hypotensive effect in rats. Psychopharmacology. 1973;28:269-274.
11. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Hewlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-613.
12. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932-1936.
13. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
14. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human brain cannabinoid receptor which is also expressed in testis. Biochem J. 1991;279:129-134.
15. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
16. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, LeFur G, Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 1995;270:3726-3731.
17. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1993;48:655-669.
18. Mailleux P, Parmentier M, Vanderhaeghen JJ. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett. 1992;143:200-204.
19. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
20. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem. 1993;61:352-355.
21. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Scei U S A. 1993;90:7656-7660.
22. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 1993;231:313-314.
23. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 1994;270: 219-227.
24. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 1995;278:279-283.
25. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118:2023-2028.
26. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension. 1996;28:682-686.
27. Sitsen JMA, Van Ree JM, de Jong W. Cardiovascular and respiratory effects of β-endorphin in anesthetized and conscious rats. J Cardiovasc Pharmacol. 1982;4:883-889.
28. Maggi CA, Meli A. Suitability of urethane for physiopharmacological investigations in various systems. Experientia. 1986;42:109-115.
29. DeLean A, Munson P, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1977; 235:E97-E102.
30. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244.
31. 9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther. 1976;96:649-656.
32. Adams MD, Earnhardt JT, Martin BR, Harris LS, Dewey WL, Razdan RK. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia. 1977;33:1204-1205.
33. Zaugg HE, Kyncl J. New antihypertensive cannabinoids. J Med Chem. 1983;26:214-217.
34. Adams IB, Thomas BF, Compton DR, Razdan RK, Martin BR. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther. 1995;273: 1172-1181.
35. Rosenkrantz H. Cannabis, marijuana, and cannabinoid toxicological manifestations in man and animals. In: O'Brien K, Kalant H, eds. Cannabis and Health Hazards. Toronto. Canada: Addiction Research Foundation; 1983:91-175.
36. 9-trans-tetrahydrocannabinol. Res Commun Chem Palhol Pharmacol. 1972;3:483-492.
37. Mosqueda-Garcia R, Kunos G. Opiate receptors and the endorphin-mediated cardiovascular effects of clonidine in rats: evidence for hypertension-induced μ-subtype to delta-subtype changes. Proc Natl Acad Sci U S A. 1987;84:8637-8641.
38. Kawasaki H, Takasaki K. Central α-2 adrenoceptor-mediated hypertensive response to clonidine in conscious, normotensive rats. J Pharmacol Exp Ther. 1986;236:810-818.
39. Carruba MO, Bondiolotti G, Picotti GB, Catteruccia N, Prada M. Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. Eur J Pharmacol. 1987;134:15-24.
40. Judy WV, Watanabe AM, Henry DP, Besch HR Jr, Murphy WR, Hockel GM. Sympathetic nerve activity: role in regulation of blood pressure in the spontaneously hypertensive rat. Circ Res. 1976; 38(suppl II):II-21-II-29.
41. Smiley KA, Karler R, Turkanis SA. Effects of cannabinoids on the perfused rat heart. Res Commun Chem Pathol Pharmacol. 1976;12: 659-675.